Somatostatin Analogs Market Size, Trends and Insights By Type (Lanreotide, Octreotide, Pasireotide), By Application (Neuroendocrine Tumors (NETs), Acromegaly, Others), By End User (Pharmaceutical Companies, Hospitals), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2022–2030


Report Code: CMI17450

Published Date: August 2022

Pages: 220+

Category: Pharmaceuticals

Reports Description

In 2021, the global Somatostatin Analogs market was estimated at USD 5.8 billion and is projected to reach approximately USD 10 billion by 2030 with a compound annual growth rate (CAGR) of roughly 6.5% between 2022 and 2030.

The report studies the Somatostatin Analogsmarket’s drivers and restraints, coupled with the impact they have on demand during the projection period. Additionally, the report analyzes global opportunities present in the somatostatin Analogsmarket.

Somatostatin Analogs Market Size

To learn more about this report, 

Somatostatin AnalogsMarket: Overview

A somatostatin analog is a drug that reduces the body’s massive hormone discharge. It is an artificial synthetic form of somatostatin. Acromegaly and Neuroendocrine Tumors (NETs), a rare hormonal disorder, produce massive amounts of hormones in the body, and somatostatin analogs are a potential treatment for the disorder. As a result, the somatostatin analogs market is expected to thrive in the near future.

Somatostatin Analogs Market: COVID – 19 Impact Analysis

Pharmaceutical and biotech companies, in association with governments worldwide, are attempting to deal with the COVID-19 outbreak, from vaccine development to planning for medicine supply chain challenges. Approximately 115 vaccine candidates, as well as 155 molecules, are currently in the R&D pipeline. Furthermore, commonly used drugs, including hydroxychloroquine, have seen a dramatic increase in demand for COVID-19 management. Because many developed countries are running low on these drugs, there is a big potential for manufacturers of COVID-19 management drugs. The pharmaceutical, as well as biotechnology industries, are projected to grow exponentially in the future due to the demand for COVID-19 vaccines and treatment drugs.

The outbreak of the COVID-19 pandemic already had a significant impact on the somatostatin analogs market in 2020. This was attributed to the direct impact on production and demand that caused supply chain and market disruption and financially impacted businesses and financial markets.

Somatostatin Analogs Market (By Application)

To learn more about this report, 

Somatostatin Analogs Market: Growth Drivers

Significant R&D investments resulting in new product launches

Increased R&D activity in the somatostatin analogs market has resulted in increased use of already existing drug molecules. Furthermore, for these R&D activities, companies generate research funding and market investments, which positively impact market growth. Around 80, 25, and 10 clinical studies (Active/Recruiting) on Octreotide, Lanreotide, and Pasireotide, respectively, as of November 2019. Furthermore, 38 clinical studies on Acromegaly are being conducted, with 27 of them involving the use of Somatostatin Analogs. Similarly, 1,075 clinical studies on neuroendocrine tumors are being conducted, with 85 involving the use of somatostatin analogs.

Supportive government insurance policies

Another important factor driving the market growth is the availability of favorable government insurance policies and schemes for patients with rare diseases. For example, the NIH and the NCATS provide subsidized medicines for rare diseases in the United States and Europe.

Somatostatin Analogs Market: Segmentation Analysis

In our research scope, the somatostatin analogs market is segmented into type, application, and end user. By type, the market is categorized into octreotide, lanreotide, and pasireotide. Because of its various therapeutic applications, such as acromegaly, carcinoid tumors, and vasoactive intestinal peptide tumors, octreotide dominated the overall type segment in 2021. Sandostatin is Novartis AG’s first approved somatostatin analog.

The availability of generic Sandostatin in the market is expected to have an impact on its market share over the forecast period. Because of its efficacy in patients with Cushing syndrome and acromegaly, pasireotide is expected to be the fastest-growing segment during the forecast period. Furthermore, the product is at its peak sales due to its 2014 launch for acromegaly. In addition, it is being tested in phase II clinical trials for advanced/metastatic hepatocellular carcinoma.

Somatostatin Analogs Market (By End User)

To learn more about this report, 

The somatostatin analogs market is divided into three applications: acromegaly, NETs, and others. Acromegaly is expected to be the largest segment in 2021 and the fastest-growing segment during the forecast period. The growing awareness of acromegaly, combined with the availability of effective treatment options, is considered to be the primary factor driving segment growth.

Report Scope

Feature of the Report Details
Market Size in 2021 USD 5.8 Billion
Projected Market Size in 2030 USD 10 Billion
CAGR Growth Rate 6.5% CAGR
Base Year 2021
Forecast Period 2022-2030
Prominent Players Sun Pharmaceutical Industries Ltd, Camurus AB, Novartis AG, Midatech Pharma PLC, Chiasma Inc, Peptron, Inc, Ipsen Pharma, Crinetics Pharmaceuticals, Dauntless Pharmaceuticals, Teva Pharmaceuticals Inc, and Others
Key Segment By Type, Application, End User, and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Key Insights:

  • As per the analysis shared by our research analyst, the Somatostatin Analogs market is estimated to grow annually at a CAGR of around 6.5% over the forecast period (2022-2030).
  • In terms of revenue, the Somatostatin Analogs market size was valued at around USD 5.8 billion in 2021 and is projected to reach USD 10 billion by 2030. Due to a variety of driving factors, the market is predicted to rise at a significant rate.
  • Based on type segmentation, the Octreotide segment is estimated to hold a dominant market share in 2021.
  • Based on application segmentation, the acromegaly segment is projected to exhibit a higher CAGR during 2022-2030.
  • On the basis of geography, the North American region was the leading revenue generator in 2021.

Recent Development

  • July 2022: Amryt, a commercial-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the US FDA has granted Mycapssa Orphan Drug Designation for the treatment of carcinoid syndrome. The most common functional syndrome associated with neuroendocrine tumors is carcinoid syndrome.
  • June 2020: The US FDA has approved oral octreotide delayed-release capsules for the long-term maintenance treatment of acromegaly patients who previously responded to and tolerated octreotide or lanreotide injections.

Regional Landscape

North America dominated the somatostatin analog market and is expected to contribute more than 50% of total revenue. The high incidences of acromegaly and NETs are expected to be the initial driver of regional growth. Furthermore, the presence of prominent players in the region, such as Pfizer Inc. and Novartis AG, as well as rising individual awareness, are expected to drive market growth.

Over the forecast period, Asia-Pacific is expected to grow the fastest. One of the high-impact drivers for the market is an increase in the rate of NET diagnosis in countries including India, Japan, and South Korea, combined with rising per capita income.

Somatostatin Analogs Market (trends by region)

To learn more about this report, 

Competitive Landscape

To increase their revenue share, companies are focusing on strategies that include the development of new formulations, collaborations, and distribution agreements, and regional expansion.

The competitive landscape chapter provides details of all companies profiled in the report. Company overview, financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve are all included. The data points presented above are solely related to the company’s focus on the somatostatin analogs market.

The global Somatostatin Analogsmarket is segmented as follows:

By Type

  • Lanreotide
  • Octreotide
  • Pasireotide

By Application

  • Neuroendocrine Tumors (NETs)
  • Acromegaly
  • Others

By End User

  • Pharmaceutical Companies
  • Hospitals

On the basis of Geography

North America

  • The U.S.
  • Canada
  • Mexico

Europe

  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Somatostatin Analogs Market, (2022 – 2030) (USD billion)
    • 2.2 Global Somatostatin Analogs Market: snapshot
  • Chapter 3. Global Somatostatin Analogs Market – Industry Analysis
    • 3.1 Somatostatin Analogs Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Significant R&D investments resulting in new product launches
      • 3.2.2 Supportive government insurance policies
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Type
      • 3.7.2 Market attractiveness analysis By Application
      • 3.7.3 Market attractiveness analysis By End User
  • Chapter 4. Global Somatostatin Analogs Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Somatostatin Analogs Market: company market share, 2021
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Somatostatin Analogs Market – Type Analysis
    • 5.1 Global Somatostatin Analogs Market overview: By Type
      • 5.1.1 Global Somatostatin Analogs Market share, By Type, 2021 and 2030
    • 5.2 Lanreotide
      • 5.2.1 Global Somatostatin Analogs Market by Lanreotide, 2022 – 2030 (USD billion)
    • 5.3 Octreotide
      • 5.3.1 Global Somatostatin Analogs Market by Octreotide, 2022 – 2030 (USD billion)
    • 5.4 Pasireotide
      • 5.4.1 Global Somatostatin Analogs Market by Pasireotide, 2022 – 2030 (USD billion)
  • Chapter 6. Global Somatostatin Analogs Market – Application Analysis
    • 6.1 Global Somatostatin Analogs Market overview: By Application
      • 6.1.1 Global Somatostatin Analogs Market share, By Application, 2021 and 2030
    • 6.2 Neuroendocrine Tumors (NETs)
      • 6.2.1 Global Somatostatin Analogs Market by Neuroendocrine Tumors (NETs), 2022 – 2030 (USD billion)
    • 6.3 Acromegaly
      • 6.3.1 Global Somatostatin Analogs Market by Acromegaly, 2022 – 2030 (USD billion)
    • 6.4 Others
      • 6.4.1 Global Somatostatin Analogs Market by Others, 2022 – 2030 (USD billion)
  • Chapter 7. Global Somatostatin Analogs Market – End User Analysis
    • 7.1 Global Somatostatin Analogs Market overview: By End User
      • 7.1.1 Global Somatostatin Analogs Market share, By End User, 2021 and 2030
    • 7.2 Pharmaceutical Companies
      • 7.2.1 Global Somatostatin Analogs Market by Pharmaceutical Companies, 2022 – 2030 (USD billion)
    • 7.3 Hospitals
      • 7.3.1 Global Somatostatin Analogs Market by Hospitals, 2022 – 2030 (USD billion)
  • Chapter 8. Somatostatin Analogs Market – Regional Analysis
    • 8.1 Global Somatostatin Analogs Market Regional Overview
    • 8.2 Global Somatostatin Analogs Market Share, by Region, 2021 & 2030 (USD billion)
    • 8.3. North America
      • 8.3.1 North America Somatostatin Analogs Market, 2022 – 2030 (USD billion)
        • 8.3.1.1 North America Somatostatin Analogs Market, by Country, 2022 – 2030 (USD billion)
    • 8.4 North America Somatostatin Analogs Market, by Type, 2022 – 2030
      • 8.4.1 North America Somatostatin Analogs Market, by Type, 2022 – 2030 (USD billion)
    • 8.5 North America Somatostatin Analogs Market, by Application, 2022 – 2030
      • 8.5.1 North America Somatostatin Analogs Market, by Application, 2022 – 2030 (USD billion)
    • 8.6 North America Somatostatin Analogs Market, by End User, 2022 – 2030
      • 8.6.1 North America Somatostatin Analogs Market, by End User, 2022 – 2030 (USD billion)
    • 8.4. Europe
      • 8.4.2 Europe Somatostatin Analogs Market, 2022 – 2030 (USD billion)
        • 8.4.2.1 Europe Somatostatin Analogs Market, by Country, 2022 – 2030 (USD billion)
    • 8.4 Europe Somatostatin Analogs Market, by Type, 2022 – 2030
      • 8.4.1 Europe Somatostatin Analogs Market, by Type, 2022 – 2030 (USD billion)
    • 8.5 Europe Somatostatin Analogs Market, by Application, 2022 – 2030
      • 8.5.1 Europe Somatostatin Analogs Market, by Application, 2022 – 2030 (USD billion)
    • 8.6 Europe Somatostatin Analogs Market, by End User, 2022 – 2030
      • 8.6.1 Europe Somatostatin Analogs Market, by End User, 2022 – 2030 (USD billion)
    • 8.5. Asia Pacific
      • 8.5.3 Asia Pacific Somatostatin Analogs Market, 2022 – 2030 (USD billion)
        • 8.5.3.1 Asia Pacific Somatostatin Analogs Market, by Country, 2022 – 2030 (USD billion)
    • 8.4 Asia Pacific Somatostatin Analogs Market, by Type, 2022 – 2030
      • 8.4.1 Asia Pacific Somatostatin Analogs Market, by Type, 2022 – 2030 (USD billion)
    • 8.5 Asia Pacific Somatostatin Analogs Market, by Application, 2022 – 2030
      • 8.5.1 Asia Pacific Somatostatin Analogs Market, by Application, 2022 – 2030 (USD billion)
    • 8.6 Asia Pacific Somatostatin Analogs Market, by End User, 2022 – 2030
      • 8.6.1 Asia Pacific Somatostatin Analogs Market, by End User, 2022 – 2030 (USD billion)
    • 8.6. Latin America
      • 8.6.4 Latin America Somatostatin Analogs Market, 2022 – 2030 (USD billion)
        • 8.6.4.1 Latin America Somatostatin Analogs Market, by Country, 2022 – 2030 (USD billion)
    • 8.4 Latin America Somatostatin Analogs Market, by Type, 2022 – 2030
      • 8.4.1 Latin America Somatostatin Analogs Market, by Type, 2022 – 2030 (USD billion)
    • 8.5 Latin America Somatostatin Analogs Market, by Application, 2022 – 2030
      • 8.5.1 Latin America Somatostatin Analogs Market, by Application, 2022 – 2030 (USD billion)
    • 8.6 Latin America Somatostatin Analogs Market, by End User, 2022 – 2030
      • 8.6.1 Latin America Somatostatin Analogs Market, by End User, 2022 – 2030 (USD billion)
    • 8.7. The Middle-East and Africa
      • 8.7.5 The Middle-East and Africa Somatostatin Analogs Market, 2022 – 2030 (USD billion)
        • 8.7.5.1 The Middle-East and Africa Somatostatin Analogs Market, by Country, 2022 – 2030 (USD billion)
    • 8.4 The Middle-East and Africa Somatostatin Analogs Market, by Type, 2022 – 2030
      • 8.4.1 The Middle-East and Africa Somatostatin Analogs Market, by Type, 2022 – 2030 (USD billion)
    • 8.5 The Middle-East and Africa Somatostatin Analogs Market, by Application, 2022 – 2030
      • 8.5.1 The Middle-East and Africa Somatostatin Analogs Market, by Application, 2022 – 2030 (USD billion)
    • 8.6 The Middle-East and Africa Somatostatin Analogs Market, by End User, 2022 – 2030
      • 8.6.1 The Middle-East and Africa Somatostatin Analogs Market, by End User, 2022 – 2030 (USD billion)
  • Chapter 9. Company Profiles
    • 9.1 Sun Pharmaceutical Industries Ltd
      • 9.1.1 Overview
      • 9.1.2 Financials
      • 9.1.3 Product Portfolio
      • 9.1.4 Business Strategy
      • 9.1.5 Recent Developments
    • 9.2 Camurus AB
      • 9.2.1 Overview
      • 9.2.2 Financials
      • 9.2.3 Product Portfolio
      • 9.2.4 Business Strategy
      • 9.2.5 Recent Developments
    • 9.3 Novartis AG
      • 9.3.1 Overview
      • 9.3.2 Financials
      • 9.3.3 Product Portfolio
      • 9.3.4 Business Strategy
      • 9.3.5 Recent Developments
    • 9.4 Midatech Pharma PLC
      • 9.4.1 Overview
      • 9.4.2 Financials
      • 9.4.3 Product Portfolio
      • 9.4.4 Business Strategy
      • 9.4.5 Recent Developments
    • 9.5 Chiasma Inc
      • 9.5.1 Overview
      • 9.5.2 Financials
      • 9.5.3 Product Portfolio
      • 9.5.4 Business Strategy
      • 9.5.5 Recent Developments
    • 9.6 Peptron Inc
      • 9.6.1 Overview
      • 9.6.2 Financials
      • 9.6.3 Product Portfolio
      • 9.6.4 Business Strategy
      • 9.6.5 Recent Developments
    • 9.7 Ipsen Pharma
      • 9.7.1 Overview
      • 9.7.2 Financials
      • 9.7.3 Product Portfolio
      • 9.7.4 Business Strategy
      • 9.7.5 Recent Developments
    • 9.8 Crinetics Pharmaceuticals
      • 9.8.1 Overview
      • 9.8.2 Financials
      • 9.8.3 Product Portfolio
      • 9.8.4 Business Strategy
      • 9.8.5 Recent Developments
    • 9.9 Dauntless Pharmaceuticals
      • 9.9.1 Overview
      • 9.9.2 Financials
      • 9.9.3 Product Portfolio
      • 9.9.4 Business Strategy
      • 9.9.5 Recent Developments
    • 9.10 Teva Pharmaceuticals Inc
      • 9.10.1 Overview
      • 9.10.2 Financials
      • 9.10.3 Product Portfolio
      • 9.10.4 Business Strategy
      • 9.10.5 Recent Developments

List Of Figures

  • 1. Market research Type
  • 2. Market research methodology
  • 3. Global Somatostatin Analogs Market, 2022 – 2030 (USD billion)
  • 4. Porter’s Five Forces Analysis
  • 5. Global Somatostatin Analogs Market attractiveness, By Type
  • 6. Global Somatostatin Analogs Market attractiveness, By Application
  • 7. Global Somatostatin Analogs Market attractiveness, By End User
  • 8. Global Somatostatin Analogs Market share by Type, 2022 and 2030 (USD billion)
  • 9. Global Somatostatin Analogs Market by Lanreotide, 2022 – 2030 (USD billion)
  • 10. Global Somatostatin Analogs Market by Octreotide, 2022 – 2030 (USD billion)
  • 11. Global Somatostatin Analogs Market by Pasireotide, 2022 – 2030 (USD billion)
  • 12. Global Somatostatin Analogs Market share by Application, 2022 and 2030 (USD billion)
  • 13. Global Somatostatin Analogs Market by Neuroendocrine Tumors (NETs), 2022 – 2030 (USD billion)
  • 14. Global Somatostatin Analogs Market by Acromegaly, 2022 – 2030 (USD billion)
  • 15. Global Somatostatin Analogs Market by Others, 2022 – 2030 (USD billion)
  • 16. Global Somatostatin Analogs Market share by End User, 2022 and 2030 (USD billion)
  • 17. Global Somatostatin Analogs Market by Pharmaceutical Companies, 2022 – 2030 (USD billion)
  • 18. Global Somatostatin Analogs Market by Hospitals, 2022 – 2030 (USD billion)
  • 19. Global Somatostatin Analogs Market share, by Region, 2022 and 2030
  • 20. North America Somatostatin Analogs Market, 2022 – 2030 (USD billion)
  • 21. Europe Somatostatin Analogs Market, 2022 – 2030 (USD billion)
  • 22. Asia Pacific Somatostatin Analogs Market, 2022 – 2030 (USD billion)
  • 23. Latin America Somatostatin Analogs Market, 2022 – 2030 (USD billion)
  • 24. The Middle-East and Africa Somatostatin Analogs Market, 2022 – 2030 (USD billion)

List Of Tables

  • 1. Global Somatostatin Analogs Market: Snapshot
  • 2. Drivers of the Somatostatin Analogs Market: impact analysis
  • 3. North America Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 4. North America Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 5. North America Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 6. U.S. Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 7. U.S. Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 8. U.S. Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 9. Canada Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 10. Canada Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 11. Canada Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 12. Europe Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 13. Europe Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 14. Europe Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 15. Germany Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 16. Germany Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 17. Germany Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 18. France Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 19. France Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 20. France Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 21. U.K. Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 22. U.K. Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 23. U.K. Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 24. Italy Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 25. Italy Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 26. Italy Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 27. Spain Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 28. Spain Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 29. Spain Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 30. Rest of Europe Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 31. Rest of Europe Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 32. Rest of Europe Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 33. Asia Pacific Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 34. Asia Pacific Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 35. Asia Pacific Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 36. China Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 37. China Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 38. China Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 39. Japan Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 40. Japan Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 41. Japan Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 42. India Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 43. India Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 44. India Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 45. South Korea Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 46. South Korea Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 47. South Korea Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 48. South-East Asia Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 49. South-East Asia Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 50. South-East Asia Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 51. Rest of Asia Pacific Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 52. Rest of Asia Pacific Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 53. Rest of Asia Pacific Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 54. Latin America Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 55. Latin America Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 56. Latin America Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 57. Brazil Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 58. Brazil Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 59. Brazil Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 60. Mexico Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 61. Mexico Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 62. Mexico Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 63. Rest of Latin America Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 64. Rest of Latin America Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 65. Rest of Latin America Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 66. The Middle-East and Africa Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 67. The Middle-East and Africa Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 68. The Middle-East and Africa Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 69. GCC Countries Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 70. GCC Countries Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 71. GCC Countries Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 72. South Africa Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 73. South Africa Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 74. South Africa Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)
  • 75. Rest of Middle-East Africa Somatostatin Analogs Market Revenue, By Type, 2022 – 2030 (USD billion)
  • 76. Rest of Middle-East Africa Somatostatin Analogs Market Revenue, By Application, 2022 – 2030 (USD billion)
  • 77. Rest of Middle-East Africa Somatostatin Analogs Market Revenue, By End User, 2022 – 2030 (USD billion)

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2030

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2028
  • Market revenue estimates and forecasts up to 2028, by technology
  • Market revenue estimates and forecasts up to 2028, by application
  • Market revenue estimates and forecasts up to 2028, by type
  • Market revenue estimates and forecasts up to 2028, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

List of the prominent players in the global Somatostatin Analogsmarket:

  • Sun Pharmaceutical Industries Ltd
  • Camurus AB
  • Novartis AG
  • Midatech Pharma PLC
  • Chiasma Inc
  • Peptron, Inc
  • Ipsen Pharma
  • Crinetics Pharmaceuticals
  • Dauntless Pharmaceuticals
  • Teva Pharmaceuticals Inc

FAQs

The north American region will lead the global Somatostatin Analogs market during the forecast period 2022 to 2030.

Increased R&D activity in the somatostatin analogs market has resulted in increased use of already existing drug molecules. Furthermore, for these R&D activities, companies generate research funding and market investments, which positively impact market growth.

The key players operating in the Somatostatin Analogs market are Sun Pharmaceutical Industries Ltd, Camurus AB, Novartis AG, Midatech Pharma PLC, Chiasma Inc, Peptron, Inc, Ipsen Pharma, Crinetics Pharmaceuticals, Dauntless Pharmaceuticals, Teva Pharmaceuticals Inc, and Others.

The global Somatostatin Analogs market is expanding growth with a CAGR of approximately 6.5% during the forecast period (2022 to 2030).

The global Somatostatin Analogs market size was valued at USD 5.8 billion in 2021 and it is projected to reach around USD 10 billion by 2030.

PURCHASE OPTIONS

excel
$

3200


pdf excel
$

4200


pdf excel powerbi
$

5200


excel
$

1800

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
View cart

Find it too expensive?
NO WORRIES!